Skip to content

Immix Biopharma, Inc. IMMX Operating Lease Right-of-Use Assets in Other Assets

Operating Lease Right-of-Use Assets in Other Assets at other companies

Allogene Therapeutics logo
Allogene TherapeuticsALLO
Regenxbio logo
RegenxbioRGNX
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
Xencor logo
XencorXNCR
Immunome logo
ImmunomeIMNM
Precigen logo
PrecigenPGEN

Other financials

Income statement

See full
Operating income-$10.8M-131%
Net income-$10.1M-122%
EPS (diluted)-$0.18-20.0%

Balance sheet

See full
Cash & equivalents$79.3M+398%
Total debt$1.0M-2.0%
Total equity$84.4M+779%
Total assets$95.8M+382%

Cash flow

See full
Operating cash flow-$9.8M-483%
CapEx$32.5K-52.0%
Free cash flow-$9.9M-462%

Valuation

See full
Market cap$691.97M+1,008%
Enterprise value$613.75M+1,190%

Returns & leverage

See full
Return on equity-74.4%-18.6pp
Debt / equity-0.1×
Current ratio8.8×+7.0×

Where this comes from

Reported directly by Immix Biopharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immix Biopharma, Inc.'s operating lease right-of-use assets in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immix Biopharma, Inc.'s operating lease right-of-use assets in other assets?
Immix Biopharma, Inc. (IMMX) reported operating lease right-of-use assets in other assets of $927.73K in Q1 2026.
How has Immix Biopharma, Inc.'s operating lease right-of-use assets in other assets changed year-over-year?
Immix Biopharma, Inc.'s operating lease right-of-use assets in other assets decreased by 4.2% year-over-year, from $968.44K to $927.73K.